Bandar Alqarni/X
Sep 29, 2025, 11:36
Bandar Alqarni: Smoflipid 20% Use in IVF Protocols
Bandar Alqarni, Pharmacist in Riyadh, shared a post on X:
“Smoflipid 20% is gaining attention for its off-label use in IVF protocols, especially in cases of Recurrent Implantation Failure (RIF) or Recurrent Pregnancy Loss (RPL).
It may help by:
- Reducing NK cell activity
- Enhancing immune tolerance
- Supporting embryo implantation
While not considered a formal treatment, it is an option in select cases after ruling out organic and chromosomal causes. Its use is under strict medical supervision, often as part of an integrated immunotherapy plan.
Always consult your fertility specialist.”
-
Oct 11, 2025, 06:44The Global IVF Market Is Set to Reach $65B by 2032 – Meddilink
-
Nov 5, 2025, 13:34Nibhash Kumar: When Embryos Stop Growing and the Hidden Reasons Behind Early Developmental Arrest
-
Nov 5, 2025, 13:29Ahsan Saeed: DNA From Three Parents Just Stopped a Life-Threatening Disorder Before Birth!
-
Nov 5, 2025, 13:24New Weighted Classification Criteria Refine Antiphospholipid Syndrome Research – Hæmatologi DK
-
Nov 4, 2025, 15:34Optimal Endometrial Thickness Up to 12 mm Boosts Live Birth Rates in IVF – Fertility Plus
-
Nov 4, 2025, 15:20hCG and GnRH Analogue Trigger Show Similar Outcomes in IVF Cycles – Fertility Plus
-
Nov 4, 2025, 15:08Nyakaishiki Mercy: Pregnant Women Shouldn’t Get Leave From Work
-
Nov 4, 2025, 14:55Fewer Preeclampsia Cases Reported With Closed-Loop Insulin Use in Type 1 Diabetic Pregnancies – Medical Xpress
-
Nov 4, 2025, 14:42Meghna Rao: Exploring the Role of the Gut Microbiome in Women’s Reproductive Health
-
Nov 4, 2025, 14:23Fatemeh Zarimeidani: Advancing Care for PCOS-Related Infertility